首页> 外文期刊>The Canadian journal of hospital pharmacy. >Management of Supratherapeutic International Normalized Ratio without Bleeding after Warfarin Use: An Evaluation of Vitamin K Administration (SUPRA-WAR-K Study)
【24h】

Management of Supratherapeutic International Normalized Ratio without Bleeding after Warfarin Use: An Evaluation of Vitamin K Administration (SUPRA-WAR-K Study)

机译:华法林使用后,在不出血的情况下进行辛艾拉等国际规范化的管理:对维生素K管理的评价(Supra-War-K研究)

获取原文
获取原文并翻译 | 示例
       

摘要

Background: For patients with supratherapeutic international normalized ratio (INR) and no evidence of bleeding, the 2012 guidelines of the American College of Chest Physicians discourage administration of vitamin K. At the study hospital, it was observed that vitamin K was frequently prescribed for patients with INR of 4.5 or higher and no bleeding. Objectives: To compare efficacy and safety outcomes between holding warfarin alone and holding warfarin with administration of vitamin K and to compare these outcomes among various doses and routes of vitamin K administration in non-critical care inpatients experiencing supratherapeutic INR without evidence of bleeding. Methods: This single-centre retrospective chart review involved non-critical care inpatients with supratherapeutic INR (4.5-8.9) without evidence of bleeding. The primary outcomes were the change in INR 1 day after implementation of supratherapeutic INR management and the time to reach INR less than 3.0. The secondary outcomes were length of stay, frequency of warfarin resistance, incidence and duration of bridging anticoagulation, incidence of thromboembolism and major bleeding, and death. Results: Regardless of vitamin K dose, the administration of vitamin K combined with holding warfarin, relative to holding warfarin alone, was associated with a greater INR decrease 1 day after the intervention (mean ± standard deviation-3.2 ± 1.9 versus- 0.9 ± 1.0,p< 0.001) and ashorter time to reach INR below 3.0 (1.9 ± 1.0 days versus 2.6 ± 1.4 days, p = 0.003). No statistically significant differences in any other outcomes were observed. Conclusions: In hospitalized non-critical care patients with INR between 4.5 and 8.9 without evidence of bleeding, the combination of holding warfarin and administering vitamin K was associated with greater and faster decreases in INR than holding warfarin alone. No significant differences were found in clinically important outcomes. The practice of administering vitamin K in this population warrants further study and re-evaluation.
机译:背景:对于Supratherapeutic Internaligural的患者(INR)而且没有出血的证据,2012年美国胸部医生学院的指导方针劝阻维生素K.在研究院,观察到维生素K经常为患者开展INR为4.5或更高,没有出血。目的:在施用维生素K的施用中比较持有华法林单独和持有华法林的疗效和安全结果,并在没有出血的非关键护理住院患者中比较各种剂量和维生素K管理途径的这些结果。方法:此单中心回顾性图表审查涉及与Supratterapeutic INR(4.5-8.9)的非关键护理住院患者没有出血的证据。主要结果是在实施Suprattaleic INR管理后1天的变化以及达到小于3.0的INR的时间。二次结果是保持长度,抗抗凝,抗凝,血栓栓塞发病率和主要出血的发病率和持续时间的频率。结果:无论维生素K剂量,维生素K与单独持有华法林合并的维生素K施用与单独的持有华法林相比,干预后1天更大的INR减少(平均值±标准偏差-3.2±1.9与-0.9±1.0 ,p <0.001)和Ashorter时间达到3.0以下(1.9±1.0天,与2.6±1.4天,p = 0.003)。没有观察到任何其他结果的统计学意义差异。结论:在4.5和8.9之间的住院的非关键护理患者在4.5和8.9之间没有出血的证据,持有华法林和施用维生素K的组合与单独持有华法林的INR相关,更快地减少。在临床上没有发现显着的差异。在本人施用维生素K的实践需要进一步研究和重新评估。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号